Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTI-Amp: Optimizing PreTerm Infant Ampicillin Dosing
NCT07610486Phase 2Recruiting
- Sponsor
- Duke University
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ampicillin in sepsis, sponsored by Duke University. Primary endpoint: Total plasma ampicillin concentration at 50 hours. Started Jul 2026; status: recruiting.
02
Drugs
ampicillin
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT07610486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610486.